Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Myeloproliferative Disorders 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Rituximab 21Cyclophosphamide 21fludarabine 12fludarabine phosphate 10pirtobrutinib 6obinutuzumab 6ibrutinib 6acalabrutinib 6Tacrolimus 6Mycophenolic Acid 6Melphalan 6Magnetic Resonance Spectroscopy 6Biopsy 6venetoclax 5tocilizumab 5X-Rays 5Whole-Body Irradiation 5Specimen Handling 5Prednisone 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Etoposide 5Doxorubicin 5Thiotepa 4Lenalidomide 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Cytarabine 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Non-Hodgkin × itacitinib × Clear all
NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte Corporation

Phase 2 Active not recruiting
112 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡